Clinique Golé ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  10.0% 15.3% 12.4% 8.8% 11.4%  
Credit score (0-100)  26 13 18 27 20  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  0.0 -0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  298 0.0 197 345 527  
EBITDA  -17.1 -93.0 105 -14.5 -56.2  
EBIT  -17.1 -93.0 105 -14.5 -56.2  
Pre-tax profit (PTP)  -17.1 -93.0 105.0 -16.6 -56.3  
Net earnings  -13.4 -72.5 81.9 -16.3 -43.9  
Pre-tax profit without non-rec. items  -17.1 -93.0 105 -16.6 -56.3  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  15.3 -57.3 24.6 8.3 -35.6  
Interest-bearing liabilities  56.1 0.0 18.6 73.6 47.2  
Balance sheet total (assets)  122 94.9 96.2 148 162  

Net Debt  -9.9 -21.2 -22.0 -25.6 -52.9  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  298 0.0 197 345 527  
Gross profit growth  0.0% -100.0% 0.0% 75.2% 52.6%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  122 95 96 148 162  
Balance sheet change%  4.2% -22.3% 1.3% 54.0% 9.5%  
Added value  -17.1 -93.0 105.4 -14.5 -56.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -10 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 1.0 -1.0 -2.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -5.8% 0.0% 53.5% -4.2% -10.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -14.3% -67.8% 84.8% -11.9% -32.5%  
ROI %  -34.3% -239.1% 424.4% -23.2% -87.1%  
ROE %  -60.8% -131.6% 137.0% -99.1% -51.5%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  12.5% -37.6% 25.6% 5.6% -18.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  57.6% 22.8% -20.9% 177.0% 94.2%  
Gearing %  367.2% 0.0% 75.3% 886.3% -132.5%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 3.8% 4.5% 0.1%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.4 0.3 0.6 0.7 0.6  
Current Ratio  2.2 0.6 0.9 0.9 0.7  
Cash and cash equivalent  65.9 21.2 40.6 99.2 100.1  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  62.4 -59.8 -4.5 -15.0 -58.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0